Aliases & Classifications for Ureteral Disease

MalaCards integrated aliases for Ureteral Disease:

Name: Ureteral Disease 12 15
Ureteral Diseases 44 73
Ureteral Disorders 43
Disorder of Ureter 73

External Ids:

Disease Ontology 12 DOID:1426
MeSH 44 D014515
NCIt 50 C27148

Summaries for Ureteral Disease

MedlinePlus : 43 Your kidneys make urine by filtering wastes and extra water from your blood. The urine travels from the kidneys to the bladder in two thin tubes called ureters. The ureters are about 8 to 10 inches long. Muscles in the ureter walls tighten and relax to force urine down and away from the kidneys. Small amounts of urine flow from the ureters into the bladder about every 10 to 15 seconds. Sometimes the ureters can become blocked or injured. This can block the flow of urine to the bladder. If urine stands still or backs up the ureter, you may get a urinary tract infections. Doctors diagnose problems with the ureters using different tests. These include urine tests, x-rays, and examination of the ureter with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Ureteral Disease, also known as ureteral diseases, is related to vesicoureteral reflux 1 and penile disease. An important gene associated with Ureteral Disease is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are p70S6K Signaling and Toll-like Receptor Signaling Pathway. The drugs Tamsulosin and Ketoprofen have been mentioned in the context of this disorder. Affiliated tissues include the ureter, kidney and testes, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 A urinary system disease that is located in the ureter.

Related Diseases for Ureteral Disease

Diseases related to Ureteral Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Related Disease Score Top Affiliating Genes
1 vesicoureteral reflux 1 27.6 C16orf58 MCU PAX2 REN ROBO2 SOX17
2 penile disease 10.7 SMAD2 SMAD3 TGFB1
3 hypertrophic scars 10.7 SMAD2 SMAD3 TGFB1
4 localized scleroderma 10.7 CTGF SMAD3 TGFB1
5 multicystic dysplastic kidney 10.7 PAX2 REN
6 spastic paraplegia 3, autosomal dominant 10.7 CDH1 SMAD2 TGFB1
7 hypochondrogenesis 10.6 SMAD2 SMAD3 SMAD7
8 clear cell adenocarcinoma 10.6 PAX2 SMAD2 SMAD3
9 pauci-immune glomerulonephritis 10.6 BMP7 CTGF SMAD2
10 malignant renovascular hypertension 10.5 REN SERPINE1
11 hyporeninemic hypoaldosteronism 10.5 ACE REN
12 vitreoretinopathy, neovascular inflammatory 10.5 CCL2 CTGF TGFB1
13 keloids 10.4 SMAD2 SMAD3 SMAD7 TGFB1
14 hydronephrosis 10.4 AQP2 CCL2 TGFB1
15 ureteral obstruction 10.4 AQP2 BMP7 TGFB1
16 renal artery obstruction 10.4 ACE REN
17 hypoaldosteronism 10.3 ACE REN
18 fibromuscular dysplasia 10.3 ACE REN TGFB1
19 malignant secondary hypertension 10.3 REN SERPINE1
20 hypertensive encephalopathy 10.3 ACE REN
21 inappropriate adh syndrome 10.3 AQP2 REN
22 hepatorenal syndrome 10.3 ACE AQP2 REN
23 aortic valve disease 1 10.3 ACE REN TGFB1
24 peyronie's disease 10.2 CCL2 SMAD3 SMAD7 TGFB1
25 nephrogenic systemic fibrosis 10.2 CTGF SMAD2 SMAD3 SMAD7 TGFB1
26 hypokalemia 10.2 ACE AQP2 REN
27 polycystic kidney disease 1 with or without polycystic liver disease 10.2 ACE AQP2 REN
28 systemic scleroderma 10.2 ACE CTGF TGFB1
29 hypertensive retinopathy 10.1 ACE REN
30 microvascular complications of diabetes 3 10.1 ACE CTGF REN TGFB1
31 renal dysplasia 10.1 ACE PAX2 REN
32 silicosis 10.1 ACE CCL2 TGFB1
33 renal artery disease 10.1 ACE REN
34 idiopathic interstitial pneumonia 10.0 CCL2 CTGF SERPINE1 TGFB1
35 pulmonary fibrosis 10.0 CCL2 CTGF SMAD3 SMAD7 TGFB1
36 familial vesicoureteral reflux 10.0 ACE ROBO2 SOX17 TGFB1
37 chronic kidney failure 10.0 ACE PAX2 REN TGFB1
38 nephrosclerosis 9.9 ACE CCL2 CTGF TGFB1
39 congestive heart failure 9.9 ACE AQP2 REN
40 chagas disease 9.9 ACE CCL2 SMAD2 TGFB1
41 iga glomerulonephritis 9.9 ACE CCL2 REN TGFB1
42 transitional cell carcinoma 9.9 CDH1 UPK1B UPK3A
43 glucose metabolism disease 9.9 ACE REN SERPINE1
44 pulmonary fibrosis, idiopathic 9.8 CCL2 CDH1 CTGF SMAD2 SMAD3 TGFB1
45 hypertension, diastolic 9.7 ACE REN
46 autosomal dominant polycystic kidney disease 9.6 ACE AQP2 CCL2 CDH1 REN
47 arteries, anomalies of 9.6 ACE CCL2 REN SERPINE1
48 acquired metabolic disease 9.6 ACE CCL2 REN SERPINE1
49 stroke, ischemic 9.5 ACE BMP7 REN SERPINE1
50 urinary system disease 9.4 ACE AQP2 CCL2 CTGF REN TGFB1

Graphical network of the top 20 diseases related to Ureteral Disease:



Diseases related to Ureteral Disease

Symptoms & Phenotypes for Ureteral Disease

MGI Mouse Phenotypes related to Ureteral Disease:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 CTGF BMP7 MCU ACE CDH1 ROBO2
2 growth/size/body region MP:0005378 10.31 AQP2 CTGF BMP7 ACE CDH1 REN
3 homeostasis/metabolism MP:0005376 10.3 AQP2 CTGF MCU ACE CDH1 REN
4 endocrine/exocrine gland MP:0005379 10.21 CTGF BMP7 ACE CDH1 SMAD2 PAX2
5 mortality/aging MP:0010768 10.2 AQP2 CTGF BMP7 MCU ACE CDH1
6 digestive/alimentary MP:0005381 10.19 CTGF BMP7 CDH1 ROBO2 SMAD3 SMAD2
7 embryo MP:0005380 10.18 CTGF BMP7 CDH1 SMAD2 PAX2 SMAD7
8 hematopoietic system MP:0005397 10.18 AQP2 BMP7 ACE REN SMAD2 SERPINE1
9 immune system MP:0005387 10.17 CDH1 BMP7 CCL2 ACE REN SMAD2
10 integument MP:0010771 10.06 AQP2 CTGF BMP7 CDH1 SMAD2 SERPINE1
11 liver/biliary system MP:0005370 9.91 CTGF ACE SMAD2 SERPINE1 SOX17 SMAD3
12 normal MP:0002873 9.91 CDH1 CTGF BMP7 REN SMAD2 ROBO2
13 renal/urinary system MP:0005367 9.85 BMP7 ACE AQP2 ROBO2 SMAD3 SERPINE1
14 reproductive system MP:0005389 9.73 BMP7 ACE CDH1 AQP2 ROBO2 SMAD3
15 respiratory system MP:0005388 9.17 CTGF BMP7 SMAD2 ROBO2 MCU SERPINE1

Drugs & Therapeutics for Ureteral Disease

Drugs for Ureteral Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 106133-20-4 129211
2
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
3
Morphine Approved, Investigational Phase 4 57-27-2 5288826
4 Nefopam Approved, Investigational Phase 4 13669-70-0
5
Silodosin Approved Phase 4,Phase 2 160970-54-7
6
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
7 Naftopidil Investigational Phase 4,Phase 3 57149-07-2
8 Adrenergic Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
9 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
10 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
11 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
13 Antihypertensive Agents Phase 4,Phase 3
14 calcium channel blockers Phase 4,Phase 3
15 Calcium, Dietary Phase 4,Phase 3
16 Platelet Aggregation Inhibitors Phase 4,Phase 3
17 Analgesics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
18 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2,Not Applicable
19 Central Nervous System Depressants Phase 4,Phase 2,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
21 Vasodilator Agents Phase 4,Phase 3
22 Analgesics, Opioid Phase 4,Not Applicable
23 Narcotics Phase 4,Not Applicable
24 Anti-Inflammatory Agents Phase 4,Phase 3,Not Applicable
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Not Applicable
26 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
27 Cyclooxygenase Inhibitors Phase 4,Not Applicable
28 Cholinergic Agents Phase 4
29 Cholinergic Antagonists Phase 4
30 Muscarinic Antagonists Phase 4
31 Tolterodine tartrate Phase 4 124937-52-6
32 Phosphodiesterase 5 Inhibitors Phase 4
33 Phosphodiesterase Inhibitors Phase 4
34 Sildenafil Citrate Phase 4 171599-83-0
35 Citrate Nutraceutical Phase 4
36
Alfuzosin Approved, Investigational Phase 3,Phase 2 81403-80-7 2092
37
Doxazosin Approved Phase 3 74191-85-8 3157
38
Nifedipine Approved Phase 3 21829-25-4 4485
39
Prazosin Approved Phase 3 19216-56-9 4893
40
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
41
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
42
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
43
Aceclofenac Approved, Investigational Phase 3 89796-99-6
44
Acetaminophen Approved Phase 3 103-90-2 1983
45
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
46
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
47
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
48
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
49
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
50
Pemetrexed Approved, Investigational Phase 3,Phase 2 150399-23-8, 137281-23-3 446556 60843

Interventional clinical trials:

(show top 50) (show all 167)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones Unknown status NCT01167062 Phase 4 Tamsulosin Hydrochloride OCAS 0.4 mg
3 The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study Unknown status NCT00489112 Phase 4 Alfuzocine XL 10 mg once a day
4 Naftopidil 75mg for Improving Clearance of Urinary Stones Unknown status NCT02011737 Phase 4 naftopidil 75mg
5 Functional MR Urography Completed NCT00301470 Phase 4
6 Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi Completed NCT00639574 Phase 4 Néfopam
7 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4 Silodosin;Placebo
8 Tamsulosin for Urolithiasis in the Emergency Dept Completed NCT00382265 Phase 4 tamsulosin
9 Treatment of Upper Ureteric Stones Recruiting NCT02469766 Phase 4
10 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Active, not recruiting NCT01741454 Phase 4 Tamsulosin;Tolterodine ER
11 Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones Active, not recruiting NCT02519153 Phase 4 Sildenafil
12 Silodosin Versus Tamsulosin for Treatment of Ureteral Stones Terminated NCT02369744 Phase 4 Silodosin;Tamsulosin
13 Celecoxib (Celebrex) in the Management of Acute Renal Colic Withdrawn NCT00304317 Phase 4 celecoxib
14 Alfuzosin for Medical Expulsion Therapy of Ureteral Stones Unknown status NCT00713739 Phase 3 Alfuzosin;nifedipine;doxazosin;prazosin
15 Evaluation of Tamsulosin in the Treatment of Ureteral Stones Completed NCT00151567 Phase 3 Tamsulosin;Placebo
16 Medical Expulsive Therapy for Ureter Stone Using Naftopidil Completed NCT01952314 Phase 3 Naftopidil 75mg;Placebo for Naftopidil;Standard treatment
17 Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi Completed NCT00177086 Phase 3
18 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
19 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
20 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
21 A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Recruiting NCT03474107 Phase 3 enfortumab vedotin;docetaxel;vinflunine;paclitaxel
22 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
23 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
24 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting NCT00942331 Phase 3 Cisplatin;Gemcitabine Hydrochloride
25 Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction Unknown status NCT01823575 Phase 2
26 Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin Unknown status NCT00478998 Phase 2 Tamsulosin
27 Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy Unknown status NCT00409227 Phase 2 Alpha blocker-alfuzosin;placebo
28 A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer Unknown status NCT01326871 Phase 1, Phase 2 Cisplatin;Gemcitabine
29 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer Unknown status NCT01191892 Phase 2 carboplatin;gemcitabine hydrochloride;vandetanib;Placebo
30 Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer Unknown status NCT01118039 Phase 2 sunitinib malate
31 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium Unknown status NCT01089088 Phase 2 cisplatin;gemcitabine hydrochloride;sunitinib malate
32 Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer Unknown status NCT00005958 Phase 2 docetaxel;gemcitabine hydrochloride
33 Surgery Plus Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Urinary Tract Unknown status NCT00006111 Phase 2 cisplatin;fluorouracil
34 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
35 Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
36 Study of Silodosin to Facilitate Passage of Urinary Stones Completed NCT01144949 Phase 2 silodosin;placebo
37 Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Completed NCT00250406 Phase 2
38 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2 TRC105
39 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2 Genexol PM
40 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium Completed NCT01090466 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride;temsirolimus
41 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment Completed NCT01031875 Phase 2 pazopanib hydrochloride
42 Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer Completed NCT00792025 Phase 2 sunitinib malate
43 A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer Completed NCT00661609 Phase 2 AZD4877
44 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function Completed NCT00478361 Phase 2 Gemcitabine hydrochloride;Paclitaxel;Doxorubicin hydrochloride;Pegfilgrastim
45 Pazopanib in Treating Patients With Metastatic Urothelial Cancer Completed NCT00471536 Phase 2 pazopanib hydrochloride
46 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
47 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Completed NCT00397488 Phase 2 sunitinib malate
48 Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00310011 Phase 2 cisplatin;gemcitabine hydrochloride;paclitaxel
49 Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract Completed NCT00112671 Phase 2 sorafenib tosylate
50 Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed NCT00101608 Phase 2 vinflunine

Search NIH Clinical Center for Ureteral Disease

Cochrane evidence based reviews: ureteral diseases

Genetic Tests for Ureteral Disease

Anatomical Context for Ureteral Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Ureteral Disease:

19
The Ureter

MalaCards organs/tissues related to Ureteral Disease:

41
Kidney, Testes, Lung, Liver, Endothelial, Prostate, Bone

Publications for Ureteral Disease

Articles related to Ureteral Disease:

# Title Authors Year
1
Extensive dilation of distal ureter for endoscopic treatment of large volume ureteral disease. ( 7869503 )
1995
2
Ureteroscopy with rigid instruments in the management of distal ureteral disease. ( 6737571 )
1984
3
Ipsilateral ureteroureterostomy for single ureteral disease in patients with ureteral duplication: a review of 8 years of experience with 16 patients. ( 650746 )
1978
4
Role of the excretory urogram in the diagnosis of renal and ureteral disease. ( 4479909 )
1974
5
Transureteroureterostomy in the management of distal ureteral disease. ( 5047409 )
1972

Variations for Ureteral Disease

Expression for Ureteral Disease

Search GEO for disease gene expression data for Ureteral Disease.

Pathways for Ureteral Disease

Pathways related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.98 ACE BMP7 CCL2 CTGF REN TGFB1
2
Show member pathways
12.96 ACE CCL2 MCU SERPINE1 SMAD2 SMAD3
3
Show member pathways
12.48 BMP7 SMAD2 SMAD3 SOX17 TGFB1
4
Show member pathways
12.4 BMP7 SMAD2 SMAD3 TGFB1
5 12.29 CDH1 SMAD2 SMAD3 TGFB1
6
Show member pathways
12.26 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
7 12.13 CDH1 SMAD2 SMAD3 TGFB1
8 12.13 MCU SERPINE1 SMAD2 SMAD3 TGFB1
9 12.04 CDH1 CTGF SERPINE1 SMAD2 SMAD3
10 12.03 SMAD2 SMAD3 SMAD7 TGFB1
11 12 BMP7 SMAD2 SMAD3 TGFB1
12 11.89 CCL2 SERPINE1 SMAD2 SMAD3 TGFB1
13 11.86 SERPINE1 SMAD3 TGFB1
14 11.86 SMAD2 SMAD3 SMAD7 TGFB1
15
Show member pathways
11.8 SMAD2 SMAD3 TGFB1
16 11.8 BMP7 SMAD2 SMAD3 SMAD7 TGFB1
17 11.77 CCL2 REN TGFB1
18
Show member pathways
11.77 BMP7 CCL2 CDH1 CTGF SMAD2 SMAD3
19 11.76 BMP7 CTGF PAX2 SERPINE1 SMAD2 SMAD3
20 11.74 SERPINE1 SMAD2 SMAD3 SMAD7
21
Show member pathways
11.72 ACE REN TGFB1
22
Show member pathways
11.7 SMAD2 SMAD3 TGFB1
23 11.69 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
24
Show member pathways
11.68 SMAD2 SMAD3 SMAD7 TGFB1
25 11.66 CDH1 SMAD2 SMAD3
26 11.6 BMP7 CCL2 CTGF SMAD7 TGFB1
27 11.48 SERPINE1 SMAD2 SMAD3 SMAD7 TGFB1
28
Show member pathways
11.45 SMAD2 SMAD3 TGFB1
29 11.41 BMP7 CDH1 CTGF SERPINE1 SMAD2 SMAD3
30 11.36 CTGF SMAD2 SMAD3 SMAD7 TGFB1
31 11.24 SMAD2 SMAD3 TGFB1
32 11.16 CTGF SERPINE1 SMAD2 SMAD3
33 10.92 CDH1 SMAD2 SMAD3 TGFB1

GO Terms for Ureteral Disease

Cellular components related to Ureteral Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.91 ACE BMP7 CCL2 CDH1 CTGF EDA
2 transcription factor complex GO:0005667 9.26 SMAD2 SMAD3 SMAD7 SOX17
3 SMAD protein complex GO:0071141 9.16 SMAD2 SMAD3
4 heteromeric SMAD protein complex GO:0071144 8.62 SMAD2 SMAD3

Biological processes related to Ureteral Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.99 CCL2 CTGF SERPINE1 SOX17
2 response to estradiol GO:0032355 9.89 BMP7 CTGF TGFB1
3 response to organic substance GO:0010033 9.89 CDH1 REN TGFB1
4 BMP signaling pathway GO:0030509 9.88 BMP7 SMAD7 TGFB1
5 wound healing GO:0042060 9.88 SMAD2 SMAD3 TGFB1
6 positive regulation of gene expression GO:0010628 9.87 BMP7 CTGF EDA SMAD2 SMAD3 SOX17
7 response to glucose GO:0009749 9.86 CTGF SMAD2 TGFB1
8 transforming growth factor beta receptor signaling pathway GO:0007179 9.86 SMAD2 SMAD3 SMAD7 TGFB1
9 epithelial cell differentiation GO:0030855 9.85 BMP7 UPK1B UPK3A
10 cellular response to transforming growth factor beta stimulus GO:0071560 9.83 SMAD3 SMAD7 TGFB1
11 regulation of MAPK cascade GO:0043408 9.82 BMP7 REN TGFB1
12 positive regulation of cell differentiation GO:0045597 9.81 BMP7 CTGF SOX17
13 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.81 SMAD2 SMAD3 SMAD7 TGFB1
14 protein kinase B signaling GO:0043491 9.8 CCL2 PAX2 TGFB1
15 gastrulation GO:0007369 9.79 SMAD2 SMAD3 SOX17
16 mesoderm formation GO:0001707 9.79 BMP7 SMAD2 SMAD3
17 positive regulation of bone mineralization GO:0030501 9.78 BMP7 SMAD3 TGFB1
18 SMAD protein signal transduction GO:0060395 9.78 BMP7 SMAD2 SMAD3 TGFB1
19 positive regulation of protein import into nucleus GO:0042307 9.77 CDH1 SMAD3 TGFB1
20 embryonic pattern specification GO:0009880 9.77 BMP7 SMAD2 SMAD3
21 kidney development GO:0001822 9.77 ACE BMP7 REN ROBO2 UPK3A
22 positive regulation of epithelial to mesenchymal transition GO:0010718 9.73 BMP7 SMAD2 SMAD3 TGFB1
23 obsolete positive regulation of transcription factor import into nucleus GO:0042993 9.72 CDH1 SMAD3
24 activin receptor signaling pathway GO:0032924 9.72 SMAD2 SMAD3
25 negative regulation of cell-cell adhesion GO:0022408 9.71 CDH1 TGFB1
26 amyloid-beta metabolic process GO:0050435 9.71 ACE REN
27 signal transduction involved in regulation of gene expression GO:0023019 9.71 SMAD2 SMAD3 SOX17
28 endoderm formation GO:0001706 9.7 SMAD2 SOX17
29 negative regulation of wound healing GO:0061045 9.7 SERPINE1 SMAD3
30 pathway-restricted SMAD protein phosphorylation GO:0060389 9.7 SMAD7 TGFB1
31 lens fiber cell differentiation GO:0070306 9.69 SMAD3 TGFB1
32 angiotensin maturation GO:0002003 9.69 ACE REN
33 response to cholesterol GO:0070723 9.68 SMAD2 TGFB1
34 nodal signaling pathway GO:0038092 9.68 SMAD2 SMAD3
35 salivary gland morphogenesis GO:0007435 9.68 BMP7 TGFB1
36 primary miRNA processing GO:0031053 9.67 SMAD2 SMAD3
37 pericardium development GO:0060039 9.67 SMAD2 SMAD3
38 mesonephros development GO:0001823 9.67 BMP7 PAX2 REN
39 response to laminar fluid shear stress GO:0034616 9.66 SMAD7 TGFB1
40 metanephric collecting duct development GO:0072205 9.65 AQP2 PAX2
41 common-partner SMAD protein phosphorylation GO:0007182 9.64 SMAD2 TGFB1
42 regulation of striated muscle tissue development GO:0016202 9.64 SMAD3 TGFB1
43 embryonic foregut morphogenesis GO:0048617 9.63 SMAD2 SMAD3 SOX17
44 positive regulation of extracellular matrix assembly GO:1901203 9.62 SMAD3 TGFB1
45 mononuclear cell proliferation GO:0032943 9.58 ACE TGFB1
46 evasion or tolerance of host defenses by virus GO:0019049 9.58 SMAD3 TGFB1
47 SMAD protein complex assembly GO:0007183 9.58 SMAD2 SMAD3 TGFB1
48 paraxial mesoderm morphogenesis GO:0048340 9.57 SMAD2 SMAD3
49 endoderm development GO:0007492 9.56 SMAD2 SMAD3 SOX17 TGFB1
50 regulation of binding GO:0051098 9.33 SMAD2 SMAD3 TGFB1

Molecular functions related to Ureteral Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.76 PAX2 SMAD3 SMAD7 SOX17
2 enhancer binding GO:0035326 9.49 SMAD2 SMAD3
3 beta-catenin binding GO:0008013 9.46 CDH1 SMAD3 SMAD7 SOX17
4 BMP receptor binding GO:0070700 9.43 BMP7 TGFB1
5 co-SMAD binding GO:0070410 9.4 SMAD2 SMAD3
6 I-SMAD binding GO:0070411 9.37 SMAD2 SMAD7
7 primary miRNA binding GO:0070878 9.32 SMAD2 SMAD3
8 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.26 SMAD2 SMAD3
9 type I transforming growth factor beta receptor binding GO:0034713 9.13 SMAD2 SMAD7 TGFB1
10 transforming growth factor beta receptor binding GO:0005160 8.92 BMP7 SMAD2 SMAD3 TGFB1
11 protein binding GO:0005515 10.41 AQP2 BMP7 CCL2 CDH1 CTGF EDA

Sources for Ureteral Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....